• Product NameLY3214996
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityLY-3214996 is a otent and selective, orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, LY3214996 inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival.
• Target NameERK inhibitor
• CAS No. 1951483-29-6
• Calculated MW 453.57
• Formulation C22H27N7O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(N(CCN1CCOCC1)C2=O)(C)C3=C2C=C(S3)C4=CC=NC(NC5=CC=NN5C)=N4
  Pathways:MAPK
  Receptor:ERK1; ERK2
  Boling pt:
  Melting pt:
  Solubility:DMSO: 15 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Shripad V. Bhagwat, et al. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Cancer Research. July 2017.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting